Martin Görner
Klinikum Bielefeld(DE)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Acute Myeloid Leukemia Research, Protein Degradation and Inhibitors, Head and Neck Cancer Studies, Hematopoietic Stem Cell Transplantation
Most-Cited Works
- → Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial(2014)481 cited
- → Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial(2015)396 cited
- → HPV & head and neck cancer: a descriptive update(2009)184 cited
- → Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma(2023)130 cited
- → A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study(2008)126 cited
- → Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease(2007)96 cited
- → Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study(2018)89 cited
- → Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy—final results of the larynx organ preservation trial DeLOS-II(2018)81 cited
- → Tuning the volume of the immune response: strength and persistence of stimulation determine migration and cytokine secretion of dendritic cells(2004)73 cited
- → Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial(2021)73 cited